DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financing
"DISCO is uniquely positioned to transform cancer care"
18-Jan-2024 -
DISCO Pharmaceuticals ("DISCO"), a specialist biotech unlocking thesurfaceome of cancer cells at scale to identify new targets and develop first in class drugs, emerges from stealth. The Company, operating out of Cologne, Germany and Schlieren, Switzerland, successfully raised seed financing ...
antibodies
antibody-drug conjugate
cancer
+6